In a report released yesterday, Peter Lawson from Barclays assigned a Buy rating to Tango Therapeutics (TNGX – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $8.39.
According to TipRanks, Lawson is a 5-star analyst with an average return of 9.3% and a 47.73% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Iovance Biotherapeutics, and MacroGenics.
Currently, the analyst consensus on Tango Therapeutics is a Strong Buy with an average price target of $17.33.
See Insiders’ Hot Stocks on TipRanks >>
TNGX market cap is currently $855.7M and has a P/E ratio of -7.64.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TNGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tango Therapeutics (TNGX) Company Description:
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Rivian downgraded, Loweâs upgraded: Wall Street’s top analyst calls
- Tango Therapeutics initiated with an Overweight at Piper Sandler
- Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
